CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL)

NCT01195480 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

29

Enrollment

OTHER

Sponsor class

Stopped Due to lack of biological efficacy and CD19 CAR CTL persistence

Conditions

Acute Lymphoblastic Leukemia

Interventions

GENETIC: donor-derived EBV-specific cytotoxic T-cells (EBV-CTL) transduced with the retroviral vector SFGalpha-CD19-CD3zeta
BIOLOGICAL: Irradiated donor-derived Lymphoblastoid Cell Line

Sponsor

University College, London

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]